Jonathan Aschoff
Stock Analyst at Roth MKM
(0.47)
# 3,930
Out of 4,843 analysts
43
Total ratings
23.08%
Success rate
-35.22%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $2.70 | +307.41% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $8.62 | +143.76% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $555 → $296 | $4.70 | +6,197.87% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.72 | +946.51% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $0.92 | +1,757.92% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $1.53 | +2,845.80% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $1.07 | +1,769.16% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $336 → $176 | $1.60 | +10,900.00% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.91 | +4,306.26% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $0.26 | +10,506.06% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $7.26 | +395.87% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $360 | $3.51 | +10,156.41% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $6.15 | +387.80% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $2.74 | +7,199.27% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.25 | +522.22% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,400 → $7,200 | $0.88 | +818,081.82% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $0.83 | +859.00% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.02 | +4,861.30% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.61 | +65,452.28% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $4.31 | +781.67% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24,000 | $0.33 | +7,352,841.18% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.13 | +4,407.04% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.36 | +76.63% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $2.70
Upside: +307.41%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $8.62
Upside: +143.76%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $555 → $296
Current: $4.70
Upside: +6,197.87%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.72
Upside: +946.51%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $0.92
Upside: +1,757.92%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $1.53
Upside: +2,845.80%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $1.07
Upside: +1,769.16%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $336 → $176
Current: $1.60
Upside: +10,900.00%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.91
Upside: +4,306.26%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $0.26
Upside: +10,506.06%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $7.26
Upside: +395.87%
Mar 5, 2024
Maintains: Buy
Price Target: $75 → $360
Current: $3.51
Upside: +10,156.41%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $6.15
Upside: +387.80%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $2.74
Upside: +7,199.27%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.25
Upside: +522.22%
Feb 14, 2023
Maintains: Buy
Price Target: $2,400 → $7,200
Current: $0.88
Upside: +818,081.82%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $0.83
Upside: +859.00%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.02
Upside: +4,861.30%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.61
Upside: +65,452.28%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $4.31
Upside: +781.67%
Feb 12, 2021
Initiates: Buy
Price Target: $24,000
Current: $0.33
Upside: +7,352,841.18%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.13
Upside: +4,407.04%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $7.36
Upside: +76.63%